× Key messages Background Findings Perspectives Expert commentary


What does this study add?

  • Compared to the CGRP-antagonist trials, patients had tried a significantly greater number of preventatives and had higher HIT6 scores at baseline.
  • CGRP-antagonists reduced headache frequency to the same degree as reported in clinical trials.
  • There were no significant differences in demographic data that predicted response to therapy in the episodic and chronic migraine patient groups.
  • While there was a subset of patients who were super-responders and a subset who are non-responders, it does not appear that number of failed preventives, age, or gender are predictive of response to therapy.
  • Side effects, particularly constipation in the chronic migraine group, were more common than reported in clinical trials.